Matouk E - Search Results

1

Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor-tezacaftor-ivacaftor (Trikafta) combination.

Veit G, Roldan A, Hancock MA, Da Fonte DF, Xu H, Hussein M, Frenkiel S, Matouk E, Velkov T, Lukacs GL. Veit G, et al. Among authors: matouk e. JCI Insight. 2020 Sep 17;5(18):e139983. doi: 10.1172/jci.insight.139983. JCI Insight. 2020. PMID: 32853178 Free PMC article.

2

Mutation-specific downregulation of CFTR2 variants by gating potentiators.

Avramescu RG, Kai Y, Xu H, Bidaud-Meynard A, Schnúr A, Frenkiel S, Matouk E, Veit G, Lukacs GL. Avramescu RG, et al. Among authors: matouk e. Hum Mol Genet. 2017 Dec 15;26(24):4873-4885. doi: 10.1093/hmg/ddx367. Hum Mol Genet. 2017. PMID: 29040544 Free PMC article.

3

Structure-guided combination therapy to potently improve the function of mutant CFTRs.

Veit G, Xu H, Dreano E, Avramescu RG, Bagdany M, Beitel LK, Roldan A, Hancock MA, Lay C, Li W, Morin K, Gao S, Mak PA, Ainscow E, Orth AP, McNamara P, Edelman A, Frenkiel S, Matouk E, Sermet-Gaudelus I, Barnes WG, Lukacs GL. Veit G, et al. Among authors: matouk e. Nat Med. 2018 Nov;24(11):1732-1742. doi: 10.1038/s41591-018-0200-x. Epub 2018 Oct 8. Nat Med. 2018. PMID: 30297908 Free PMC article.

4

Mutation-specific dual potentiators maximize rescue of CFTR gating mutants.

Veit G, Da Fonte DF, Avramescu RG, Premchandar A, Bagdany M, Xu H, Bensinger D, Stubba D, Schmidt B, Matouk E, Lukacs GL. Veit G, et al. Among authors: matouk e. J Cyst Fibros. 2020 Mar;19(2):236-244. doi: 10.1016/j.jcf.2019.10.011. Epub 2019 Oct 31. J Cyst Fibros. 2020. PMID: 31678009 Free PMC article.

5

Large pH oscillations promote host defense against human airways infection.

Kim D, Liao J, Scales NB, Martini C, Luan X, Abu-Arish A, Robert R, Luo Y, McKay GA, Nguyen D, Tewfik MA, Poirier CD, Matouk E, Ianowski JP, Frenkiel S, Hanrahan JW. Kim D, et al. Among authors: matouk e. J Exp Med. 2021 Apr 5;218(4):e20201831. doi: 10.1084/jem.20201831. J Exp Med. 2021. PMID: 33533914 Free PMC article.

6

A Precision Medicine Approach to Optimize Modulator Therapy for Rare CFTR Folding Mutants.

Veit G, Velkov T, Xu H, Vadeboncoeur N, Bilodeau L, Matouk E, Lukacs GL. Veit G, et al. Among authors: matouk e. J Pers Med. 2021 Jul 7;11(7):643. doi: 10.3390/jpm11070643. J Pers Med. 2021. PMID: 34357110 Free PMC article.

7

Cystic fibrosis fatty acid imbalance is linked to ceramide deficiency and corrected by fenretinide.

Guilbault C, Wojewodka G, Saeed Z, Hajduch M, Matouk E, De Sanctis JB, Radzioch D. Guilbault C, et al. Among authors: matouk e. Am J Respir Cell Mol Biol. 2009 Jul;41(1):100-6. doi: 10.1165/rcmb.2008-0279OC. Epub 2008 Dec 4. Am J Respir Cell Mol Biol. 2009. PMID: 19059886

8

Amikacin nomogram for treatment of adult cystic fibrosis exacerbations based on an external evaluation of a population pharmacokinetic model.

Thirion DJG, Pasche V, Matouk E, Marsot A. Thirion DJG, et al. Among authors: matouk e. Pediatr Pulmonol. 2020 May;55(5):1154-1160. doi: 10.1002/ppul.24689. Epub 2020 Mar 2. Pediatr Pulmonol. 2020. PMID: 32119197

9

Alendronate once weekly for the prevention and treatment of bone loss in Canadian adult cystic fibrosis patients (CFOS trial).

Papaioannou A, Kennedy CC, Freitag A, Ioannidis G, O'Neill J, Webber C, Pui M, Berthiaume Y, Rabin HR, Paterson N, Jeanneret A, Matouk E, Villeneuve J, Nixon M, Adachi JD. Papaioannou A, et al. Among authors: matouk e. Chest. 2008 Oct;134(4):794-800. doi: 10.1378/chest.08-0608. Epub 2008 Jul 18. Chest. 2008. PMID: 18641106 Free PMC article. Clinical Trial.

10

Candidate markers associated with the probability of future pulmonary exacerbations in cystic fibrosis patients.

Wojewodka G, De Sanctis JB, Bernier J, Bérubé J, Ahlgren HG, Gruber J, Landry J, Lands LC, Nguyen D, Rousseau S, Benedetti A, Matouk E, Radzioch D. Wojewodka G, et al. Among authors: matouk e. PLoS One. 2014 Feb 12;9(2):e88567. doi: 10.1371/journal.pone.0088567. eCollection 2014. PLoS One. 2014. PMID: 24533110 Free PMC article.

11

Corticosteroid-resistant inflammatory signalling in Pseudomonas-infected bronchial cells.

Mizutani M, Bérubé J, Ahlgren HG, Bernier J, Matouk E, Nguyen D, Rousseau S. Mizutani M, et al. Among authors: matouk e. ERJ Open Res. 2017 Jun 19;3(2):00144-2016. doi: 10.1183/23120541.00144-2016. eCollection 2017 Apr. ERJ Open Res. 2017. PMID: 28656134 Free PMC article.

12

Fenretinide differentially modulates the levels of long- and very long-chain ceramides by downregulating Cers5 enzyme: evidence from bench to bedside.

Garić D, De Sanctis JB, Wojewodka G, Houle D, Cupri S, Abu-Arish A, Hanrahan JW, Hajduch M, Matouk E, Radzioch D. Garić D, et al. Among authors: matouk e. J Mol Med (Berl). 2017 Oct;95(10):1053-1064. doi: 10.1007/s00109-017-1564-y. Epub 2017 Jul 10. J Mol Med (Berl). 2017. PMID: 28695226 Clinical Trial.

13

Internal consistency reliability and predictive validity of a modified N. Huang clinical scoring system in adult cystic fibrosis patients.

Matouk E, Ghezzo RH, Gruber J, Hidvegi R, Gray-Donald K. Matouk E, et al. Eur Respir J. 1997 Sep;10(9):2004-13. doi: 10.1183/09031936.97.10092004. Eur Respir J. 1997. PMID: 9311493 Free article.

14

Construct and longitudinal validity of a modified Huang clinical scoring system in adult cystic fibrosis patients.

Matouk E, Ghezzo RH, Gruber J, Hidvegi R, Gray-Donald K. Matouk E, et al. Eur Respir J. 1999 Mar;13(3):552-9. doi: 10.1183/09031936.99.13355299. Eur Respir J. 1999. PMID: 10232425 Free article.

15

Clinical outcomes associated with Staphylococcus aureus and Pseudomonas aeruginosa airway infections in adult cystic fibrosis patients.

Ahlgren HG, Benedetti A, Landry JS, Bernier J, Matouk E, Radzioch D, Lands LC, Rousseau S, Nguyen D. Ahlgren HG, et al. Among authors: matouk e. BMC Pulm Med. 2015 Jun 21;15:67. doi: 10.1186/s12890-015-0062-7. BMC Pulm Med. 2015. PMID: 26093634 Free PMC article.

16

Cystic fibrosis-adapted Pseudomonas aeruginosa quorum sensing lasR mutants cause hyperinflammatory responses.

LaFayette SL, Houle D, Beaudoin T, Wojewodka G, Radzioch D, Hoffman LR, Burns JL, Dandekar AA, Smalley NE, Chandler JR, Zlosnik JE, Speert DP, Bernier J, Matouk E, Brochiero E, Rousseau S, Nguyen D. LaFayette SL, et al. Among authors: matouk e. Sci Adv. 2015 Jul;1(6):e1500199. doi: 10.1126/sciadv.1500199. Epub 2015 Jul 31. Sci Adv. 2015. PMID: 26457326 Free PMC article.

17

C-Reactive Protein in Stable Cystic Fibrosis: An Additional Indicator of Clinical Disease Activity and Risk of Future Pulmonary Exacerbations.

Matouk E, Nguyen D, Benedetti A, Bernier J, Gruber J, Landry J, Rousseau S, Ahlgren HG, Lands LC, Wojewodka G, Radzioch D. Matouk E, et al. J Pulm Respir Med. 2016 Oct 14;6(5):1000375. doi: 10.4172/2161-105X.1000375. J Pulm Respir Med. 2016. PMID: 28066689 Free PMC article.

18

New Recommendations of a Height-Based Dosing Regimen of Tobramycin for Cystic Fibrosis in Adults: A Population Pharmacokinetic Analysis.

Koloskoff K, Thirion DJG, Matouk E, Marsot A. Koloskoff K, et al. Among authors: matouk e. Ther Drug Monit. 2023 Apr 1;45(2):251-258. doi: 10.1097/FTD.0000000000001021. Ther Drug Monit. 2023. PMID: 36070759

19

Multicenter, open-label study of recombinant human DNase in cystic fibrosis patients with moderate lung disease. DNase International Study Group.

Harms HK, Matouk E, Tournier G, von der Hardt H, Weller PH, Romano L, Heijerman HG, FitzGerald MX, Richard D, Strandvik B, Kolbe J, Kraemer R, Michalsen H. Harms HK, et al. Among authors: matouk e. Pediatr Pulmonol. 1998 Sep;26(3):155-61. doi: 10.1002/(sici)1099-0496(199809)26:3<155::aid-ppul1>3.0.co;2-k. Pediatr Pulmonol. 1998. PMID: 9773909 Clinical Trial.

20

Fenretinide corrects newly found ceramide deficiency in cystic fibrosis.

Guilbault C, De Sanctis JB, Wojewodka G, Saeed Z, Lachance C, Skinner TA, Vilela RM, Kubow S, Lands LC, Hajduch M, Matouk E, Radzioch D. Guilbault C, et al. Among authors: matouk e. Am J Respir Cell Mol Biol. 2008 Jan;38(1):47-56. doi: 10.1165/rcmb.2007-0036OC. Epub 2007 Jul 26. Am J Respir Cell Mol Biol. 2008. PMID: 17656682

21

Down-regulation of IL-8 by high-dose vitamin D is specific to hyperinflammatory macrophages and involves mechanisms beyond up-regulation of DUSP1.

Dauletbaev N, Herscovitch K, Das M, Chen H, Bernier J, Matouk E, Bérubé J, Rousseau S, Lands LC. Dauletbaev N, et al. Among authors: matouk e. Br J Pharmacol. 2015 Oct;172(19):4757-71. doi: 10.1111/bph.13249. Br J Pharmacol. 2015. PMID: 26178144 Free PMC article.

22

Genetic modifiers of liver disease in cystic fibrosis.

Bartlett JR, Friedman KJ, Ling SC, Pace RG, Bell SC, Bourke B, Castaldo G, Castellani C, Cipolli M, Colombo C, Colombo JL, Debray D, Fernandez A, Lacaille F, Macek M Jr, Rowland M, Salvatore F, Taylor CJ, Wainwright C, Wilschanski M, Zemková D, Hannah WB, Phillips MJ, Corey M, Zielenski J, Dorfman R, Wang Y, Zou F, Silverman LM, Drumm ML, Wright FA, Lange EM, Durie PR, Knowles MR; Gene Modifier Study Group. Bartlett JR, et al. JAMA. 2009 Sep 9;302(10):1076-83. doi: 10.1001/jama.2009.1295. JAMA. 2009. PMID: 19738092 Free PMC article.

23

Surgical decompression of a tension pneumomediastinum. A ventilatory complication of status asthmaticus.

Shennib HF, Barkun AN, Matouk E, Blundell PE. Shennib HF, et al. Among authors: matouk e. Chest. 1988 Jun;93(6):1301-2. doi: 10.1378/chest.93.6.1301. Chest. 1988. PMID: 3286149

24

Development and Evaluation of a Height-Based Tobramycin Initial Dosing Nomogram for the Treatment of Adult Cystic Fibrosis Pulmonary Exacerbations.

El Hassani M, Thirion DJG, Koloskoff K, Matouk E, Simard C, Cloutier I, Pilote S, Marsot A. El Hassani M, et al. Among authors: matouk e. Ther Drug Monit. 2023 Apr 1;45(2):259-264. doi: 10.1097/FTD.0000000000001053. Ther Drug Monit. 2023. PMID: 36730982

25

Computed tomography reveals hypertrophic remodelling of the diaphragm in cystic fibrosis but not in COPD.

Ostadan F, Donovan AA, Matouk E, David FG, Marchand D, Reinhold C, Nguyen D, Goldberg P, Benedetti A, Smith BM, Petrof BJ. Ostadan F, et al. Among authors: matouk e. ERJ Open Res. 2023 Sep 25;9(5):00282-2023. doi: 10.1183/23120541.00282-2023. eCollection 2023 Sep. ERJ Open Res. 2023. PMID: 37753287 Free PMC article.

26

Modulatory effect of the SLC9A3 gene on susceptibility to infections and pulmonary function in children with cystic fibrosis.

Dorfman R, Taylor C, Lin F, Sun L, Sandford A, Paré P, Berthiaume Y, Corey M, Durie P, Zielenski J; Members of Canadian Consortium for CF Genetic Studies. Dorfman R, et al. Pediatr Pulmonol. 2011 Apr;46(4):385-92. doi: 10.1002/ppul.21372. Epub 2010 Oct 21. Pediatr Pulmonol. 2011. PMID: 20967843

27

Tuberculosis of the orbit.

Khalil M, Lindley S, Matouk E. Khalil M, et al. Among authors: matouk e. Ophthalmology. 1985 Nov;92(11):1624-7. doi: 10.1016/s0161-6420(85)33818-6. Ophthalmology. 1985. PMID: 4080333

28

Diagnosing coccidioidomycosis outside an endemic area. A recent case in Montreal, Quebec, Canada.

Kapica L, Matouk E, D'Halewyn MA. Kapica L, et al. Among authors: matouk e. Mycopathologia. 1983 May 22;82(2):95-9. doi: 10.1007/BF00437337. Mycopathologia. 1983. PMID: 6888502

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

28 results

Search Page